Key result
Non-vitamin K antagonist oral anticoagulants use was associated with a significantly increased risk of acute kidney injury compared to non-use (adjusted HR 1.41).
Why the study?
Epidemiologic evidence on the risk of acute kidney injury associated with NOACs compared with warfarin users and non-users is inconsistent and limited.
Does the use of non-vitamin K antagonist oral anticoagulants increase the risk of acute kidney injury compared to non-use or warfarin in adult patients with indications for oral anticoagulants?
Cohort (n=127,334)
Yes
Does the use of non-vitamin K antagonist oral anticoagulants increase the risk of acute kidney injury compared to non-use or warfarin in adult patients with indications for oral anticoagulants?
Hazard Ratio: 1.41 (95% CI 1.27–1.57)
Absolute Event Rate: 5% vs 4%
In patients with indications for oral anticoagulants, NOAC use is associated with a higher risk of acute kidney injury compared to non-use, highlighting the need for renal function monitoring.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a cohort in Indications for oral anticoagulants (e.g., atrial fibrillation, deep vein thrombosis, pulmonary embolism) (n=127,334). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Non-users (including warfarin users and patients who did not receive oral anticoagulants) was evaluated on Acute kidney injury (AKI) (HR 1.41, 95% CI 1.27-1.57). Non-vitamin K antagonist oral anticoagulants use was associated with a significantly increased risk of acute kidney injury compared to non-use (adjusted HR 1.41).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: